Swedish natalizumab (Tysabri) multiple sclerosis surveillance study

Neurological Sciences

Volumn 31, Issue SUPPL. 3, 2010, Pages

  Piehl, Fredrik ^a   Holmen C ^a   Hillert, J ^a   Olsson, T ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Antibodies, monoclonals adverse effects; Antibodies, monoclonals therapeutic use; Multiple sclerosis; Natalizumab; Product surveillance

Indexed keywords

MONOCLONAL ANTIBODY; NATALIZUMAB;

ADULT; ARTICLE; BREATHING DISORDER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; FEMALE; HUMAN; IMMUNOLOGY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; POSTMARKETING SURVEILLANCE; REGISTER; SWEDEN;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; MALE; MULTIPLE SCLEROSIS; PRODUCT SURVEILLANCE, POSTMARKETING; REGISTRIES; RESPIRATION DISORDERS; SWEDEN;

EID: 79960379991     PISSN: 15901874     EISSN: 15903478     Source Type: Journal    
DOI: 10.1007/s10072-010-0345-y     Document Type: Conference Paper

References (17)

1. Yednock TA et al (1992) Prevention of experimental autoimmune encephalomyelitis by antibodies against α4β1 integrin. Nature 356:63-66
2. Polman CH et al (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354:899-910
3. Rudick RA et al (2006) Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 354:911-923
4. Lindå H et al (2009) Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J Med 361:1081-1087
5. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInf ormationforPatientsandProviders/ucm199872.htm
6. Roxburgh RH et al (2005) Multiple sclerosis severity score: using disability and disease duration to rate disease severity. Neurology 64(7):1144-1151
7. Hobart JC et al (2005) How responsive is the multiple sclerosis impact scale (MSIS-29)? A comparison with some other self report scales. J Neurol Neurosurg Psychiatry 76(11):1539-1543 (Pubitemid 41531702)
8. Riazi A et al (2002) Multiple sclerosis impact scale (MSIS-29): reliability and validity in hospital based samples. J Neurol Neurosurg Psychiatry 73(6):701-704 (Pubitemid 35448855)
9. Benedict RH et al (2008) Repeated assessment of neuropsychological deficits in multiple sclerosis using the Symbol Digit Modalities Test and the MS Neuropsychological Screening Questionnaire. Mult Scler 14(7):940-946
10. Parmenter BA et al (2007) Screening for cognitive impairment in multiple sclerosis using the symbol digit modalities test. Mult Scler 13(1):52-57 (Pubitemid 46152761)
11. Mancardi GL et al (2008) Natalizumab: a country-based surveillance program. Neurol Sci 29(Suppl 2):S235-S237
12. Tedeschi G et al (2009) The pharmacovigilance program on natalizumab in Italy: 2 years of experience. Neurol Sci 30(Suppl 2): S163-S165
13. Oturai AB et al (2009) Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study. Eur J Neurol 16(3):420-423
14. Putzki N et al (2009) Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis. Eur J Neurol 16(3):424-426
15. Outteryck O et al (2010) Demographic and clinic characteristics of French patients treated with natalizumab in clinical practice. J Neurol 257(2):207-211
16. Goodman AD et al (2009) GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study. Neurology 72(9):806-812
17. Calabresi PA et al (2007) The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology 69(14):1391-1403 (Pubitemid 47511460)